Rising Drug Costs, FDA Updates Highlight SPT Week in Review

5. Solvent Exposure May Be Linked to Significantly Greater Risk of MS

Exposure to organic solvents and cigarette smoking, in addition to having certain multiple sclerosis (MS) susceptibility genes, may create a 30-fold increased risk of developing the disease. Read more.

4. New Data Demonstrate Efficacy of Investigational Drug for Episodic Cluster Headache, Migraine

Galcanezumab-gnlm (Emgality, Eli Lilly) demonstrated positive results in the treatment of patients with cluster headache and migraine, according to results from a phase 3 study and post-hoc analysis. Read more.

3. New Test Could Help Diagnose Hepatitis B in Resource-Limited Countries

A newly-developed accurate and inexpensive diagnostic score may help identify thousands of patients with hepatitis B virus (HBV) who require immediate treatment in resource-limited countries. Read more.

2. FDA Updates Fluoroquinolone Warnings for Mental Health, Hypoglycemia Risks

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances. Read more.

1. Costs Rise for Medicare Part D's Top 10 Drugs with Highest Spend

Federal spending and out-of-pocket costs are steadily increasing for some of the most expensive medications in the Medicare Part D program. Read more.